These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 8331797

  • 1. [Ca-antagonist, K-channel-opener in the treatment of patients with congestive heart failure].
    Satoh K.
    Nihon Rinsho; 1993 May; 51(5):1293-8. PubMed ID: 8331797
    [Abstract] [Full Text] [Related]

  • 2. [The vasospasmolytic effects of nicorandil, cromakalim and pinacidil on 3,4-diaminopyridine-induced phasic contractions in canine coronary arteries as an experimental vasospasm model].
    Kamijo T, Tomaru T, Miwa A, Nakamura F, Kido H, Sugimoto T, Uchida Y.
    Nihon Yakurigaku Zasshi; 1992 Oct; 100(4):317-27. PubMed ID: 1446882
    [Abstract] [Full Text] [Related]

  • 3. Cytoplasmic calcium and the relaxation of canine coronary arterial smooth muscle produced by cromakalim, pinacidil and nicorandil.
    Yanagisawa T, Teshigawara T, Taira N.
    Br J Pharmacol; 1990 Sep; 101(1):157-65. PubMed ID: 2149290
    [Abstract] [Full Text] [Related]

  • 4. Cromakalim, a potassium channel activator: a comparison of its cardiovascular haemodynamic profile and tissue specificity with those of pinacidil and nicorandil.
    Longman SD, Clapham JC, Wilson C, Hamilton TC.
    J Cardiovasc Pharmacol; 1988 Sep; 12(5):535-42. PubMed ID: 2468052
    [Abstract] [Full Text] [Related]

  • 5. Potassium channel activator drugs: mechanism of action, pharmacological properties, and therapeutic potential.
    Longman SD, Hamilton TC.
    Med Res Rev; 1992 Mar; 12(2):73-148. PubMed ID: 1535674
    [No Abstract] [Full Text] [Related]

  • 6. Effect of three novel K+ channel openers, cromakalim, pinacidil and nicorandil on allergic reaction and experimental asthma.
    Nagai H, Kitagaki K, Goto S, Suda H, Koda A.
    Jpn J Pharmacol; 1991 May; 56(1):13-21. PubMed ID: 1831870
    [Abstract] [Full Text] [Related]

  • 7. Effects of ATP-sensitive K+ channel openers on pacemaker activity in isolated single rabbit sino-atrial node cells.
    Satoh H.
    J Cardiovasc Pharmacol; 1993 Dec; 22(6):863-8. PubMed ID: 7509906
    [Abstract] [Full Text] [Related]

  • 8. Pharmacology and structure-activity relationships for KATP modulators: tissue-selective KATP openers.
    Atwal KS.
    J Cardiovasc Pharmacol; 1994 Dec; 24 Suppl 4():S12-7. PubMed ID: 7898103
    [Abstract] [Full Text] [Related]

  • 9. Potassium channel modulation: a new drug principle for regulation of smooth muscle contractility. Studies on isolated airways and arteries.
    Nielsen-Kudsk JE.
    Dan Med Bull; 1996 Dec; 43(5):429-47. PubMed ID: 8960816
    [Abstract] [Full Text] [Related]

  • 10. Effects of K-channel openers on the contractility and electrical activity of antral circular muscle in guinea-pig stomach.
    Kim KW, Kim SJ, Jun JY.
    J Smooth Muscle Res; 1993 Oct; 29(5):145. PubMed ID: 8167416
    [No Abstract] [Full Text] [Related]

  • 11. Specific antagonism by glibenclamide of negative inotropic effects of potassium channel openers in canine atrial muscle.
    Satoh E, Yanagisawa T, Taira N.
    Jpn J Pharmacol; 1990 Oct; 54(2):133-41. PubMed ID: 2150209
    [Abstract] [Full Text] [Related]

  • 12. Comparative effects of K+ channel blockade on the vasorelaxant activity of cromakalim, pinacidil and nicorandil.
    Wilson C, Coldwell MC, Howlett DR, Cooper SM, Hamilton TC.
    Eur J Pharmacol; 1988 Aug 02; 152(3):331-9. PubMed ID: 2851450
    [Abstract] [Full Text] [Related]

  • 13. [Potassium channel openers. A new possible therapeutic principle in several diseases].
    Drottning P, Christensen H, Storstein L.
    Tidsskr Nor Laegeforen; 1994 Feb 10; 114(4):450-3. PubMed ID: 8009483
    [Abstract] [Full Text] [Related]

  • 14. [Potassium channel activators. Perspectives in the treatment of arterial hypertension].
    Giudicelli JF, Richer C, Berdeaux A.
    Presse Med; 1991 Jan 19; 20(2):75-81. PubMed ID: 1825708
    [Abstract] [Full Text] [Related]

  • 15. K+ channel-opening action contributes to the preventive effects of nicorandil on U46619-induced vasoconstriction of canine large coronary arteries in vivo.
    Kamijo T, Iwai T, Haruta K, Takeda K.
    Arch Int Pharmacodyn Ther; 1996 Jan 19; 331(3):273-84. PubMed ID: 9124999
    [Abstract] [Full Text] [Related]

  • 16. ATP sensitive potassium channel openers are of potential benefit in ischaemic heart disease.
    Cavero I, Premmereur J.
    Cardiovasc Res; 1994 Jan 19; 28(1):32-3. PubMed ID: 8111790
    [No Abstract] [Full Text] [Related]

  • 17. The negative inotropic effect of nicorandil is independent of cyclic GMP changes: a comparison with pinacidil and cromakalim in canine atrial muscle.
    Yanagisawa T, Hashimoto H, Taira N.
    Br J Pharmacol; 1988 Oct 19; 95(2):393-8. PubMed ID: 2852521
    [Abstract] [Full Text] [Related]

  • 18. KATP channel modulators increase survival rate during coronary occlusion-reperfusion in anaesthetized rats.
    Baczkó I, Leprán I, Papp JG.
    Eur J Pharmacol; 1997 Apr 11; 324(1):77-83. PubMed ID: 9137916
    [Abstract] [Full Text] [Related]

  • 19. Characterization of the vasodilatation by the K+ channel openers: cromakalim and pinacidil.
    Rhim BY, Lee WS, Hong KW.
    Jpn J Pharmacol; 1992 Apr 11; 58 Suppl 2():335P. PubMed ID: 1507584
    [No Abstract] [Full Text] [Related]

  • 20. The resistance of some rat cerebral arteries to the vasorelaxant effect of cromakalim and other K+ channel openers.
    McPherson GA, Stork AP.
    Br J Pharmacol; 1992 Jan 11; 105(1):51-8. PubMed ID: 1534504
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.